Chimeric antigen receptor-T (CAR-T) cell therapy is a novel adoptive cellular therapy
involving the use of CARs (recombinant fusion proteins) that activate T cells upon
the recognition of specific antigens resulting in the killing of target cancer cells
[
[1]
,
[2]
]. CD-19-specific CAR-T cell therapy has revolutionised the care of patients with
refractory and relapsing haematological malignancies [
[3]
,
[4]
]. However, CAR-T cell therapy has significant cardiac adverse effects including cardiac
arrhythmias, heart failure, and QT prolongation [
[5]
,
[6]
]. Current data about cardiovascular adverse events of CAR-T cell therapy are limited
to small observational studies and case reports. In this report, we investigated the
association of arrhythmias among hospitalised patients undergoing CAR-T cell therapy
using a nationwide, contemporary administrative claims database. We hypothesised that
patients undergoing CAR-T cell therapy will have a significant association with cardiac
arrhythmias as compared to propensity-matched controls.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Chimeric antigen receptor therapy.N Engl J Med. 2018; 379: 64-73https://doi.org/10.1056/NEJMra1706169
- Chimeric antigen receptors modified T-cells for cancer therapy.J Natl Cancer Inst. 2016; 108 (Published 2016 Jan 27. https://doi.org/10.1093/jnci/djv439): djv439
- Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma.N Engl J Med. 2017; 377: 2531-2544
- Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma.N Engl J Med. 2019; 380: 45-56https://doi.org/10.1056/NEJMoa1804980
- CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?.JACC CardioOncol. 2020; 2: 97-109
- Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.Eur Heart J. 2022; 43: 1928-1940
- Cardiovascular complications of chimeric antigen receptor T-cell therapy: the cytokine release syndrome and associated arrhythmias.J Immunother Precis Oncol. 2020; 3 (Published 2020 Jul 20. https://doi.org/10.36401/JIPO-20-10): 113-120
- Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy.J Am Coll Cardiol. 2021; 78: 1800-1813
Article info
Publication history
Published online: August 20, 2022
Accepted:
July 15,
2022
Received:
June 25,
2022
Footnotes
☆Prior presentation: The current analysis was presented as a poster presentation at the Annual Meeting of the American College of Cardiology held in Washington, D.C. in April, 2022.
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
